Optimal treatment strategies for severe aplasticanaemia remain to be determined.
2
Then they were given the devastating diagnosis of aplasticanaemia.
3
We present here a patient treated for aplasticanaemia, who developed fungal arthritis of the hip and systemic candidaemia.
4
Aims: To review 10 years of local experience in treating severe aplasticanaemia with BMT and immunosuppressive therapy with emphasis on long-term outcomes.
5
These results suggest that while rIL-1 alpha can be safely administered, no significant haematologic improvement was observed in patients with severe aplasticanaemia.
6
In long-term use it carries a one in 30,000 risk of a serious side effect - the bone marrow disorder aplasticanaemia.